The association between frailty and survival in patients with pleural disease: a retrospective cohort study.
Frailty
Malignancy
Pleural disease
Pleural effusion
Survival
Journal
BMC pulmonary medicine
ISSN: 1471-2466
Titre abrégé: BMC Pulm Med
Pays: England
ID NLM: 100968563
Informations de publication
Date de publication:
16 Apr 2024
16 Apr 2024
Historique:
received:
06
12
2023
accepted:
25
03
2024
medline:
17
4
2024
pubmed:
17
4
2024
entrez:
16
4
2024
Statut:
epublish
Résumé
There are currently no data on the relationship between frailty and mortality in pleural disease. Understanding the relationship between frailty and outcomes is increasingly important for clinicians to guide decisions regarding investigation and management. This study aims to explore the relationship between all-cause mortality and frailty status in patients with pleural disease. In this retrospective analysis of a prospectively collected observational cohort study, outpatients presenting to the pleural service at a tertiary centre in Bristol, UK with a radiologically confirmed, undiagnosed pleural effusion underwent comprehensive assessment and were assigned a final diagnosis at 12 months. The modified frailty index (mFI) was calculated and participants classified as frail (mFI ≥ 0.4) or not frail (mFI ≤ 0.2). 676 participants were included from 3rd March 2008 to 29th December 2020. The median time to mortality was 490 days (IQR 161-1595). A positive association was found between 12-month mortality and frailty (aHR = 1.72, 95% CI 1.02-2.76, p = 0.025) and age ≥ 80 (aHR = 1.80, 95% CI 1.24-2.62, p = 0.002). Subgroup analyses found a stronger association between 12-month mortality and frailty in benign disease (aHR = 4.36, 95% CI 2.17-8.77, p < 0.0001) than in all pleural disease. Malignancy irrespective of frailty status was associated with an increase in all-cause mortality (aHR = 10.40, 95% CI 6.01-18.01, p < 0.0001). This is the first study evaluating the relationship between frailty and outcomes in pleural disease. Our data demonstrates a strong association between frailty and 12-month mortality in this cohort. A malignant diagnosis is an independent predictor of 12-month mortality, irrespective of frailty status. Frailty was also strongly associated with 12-month mortality in patients with a benign underlying cause for their pleural disease. This has clinical relevance for pleural physicians; evaluating patients' frailty status and its impact on mortality can guide clinicians in assessing suitability for invasive investigation and management. This study is registered with the Health Research Authority (REC reference 08/H0102/11) and the NIHR Portfolio (Study ID 8960).
Sections du résumé
BACKGROUND
BACKGROUND
There are currently no data on the relationship between frailty and mortality in pleural disease. Understanding the relationship between frailty and outcomes is increasingly important for clinicians to guide decisions regarding investigation and management. This study aims to explore the relationship between all-cause mortality and frailty status in patients with pleural disease.
METHODS
METHODS
In this retrospective analysis of a prospectively collected observational cohort study, outpatients presenting to the pleural service at a tertiary centre in Bristol, UK with a radiologically confirmed, undiagnosed pleural effusion underwent comprehensive assessment and were assigned a final diagnosis at 12 months. The modified frailty index (mFI) was calculated and participants classified as frail (mFI ≥ 0.4) or not frail (mFI ≤ 0.2).
RESULTS
RESULTS
676 participants were included from 3rd March 2008 to 29th December 2020. The median time to mortality was 490 days (IQR 161-1595). A positive association was found between 12-month mortality and frailty (aHR = 1.72, 95% CI 1.02-2.76, p = 0.025) and age ≥ 80 (aHR = 1.80, 95% CI 1.24-2.62, p = 0.002). Subgroup analyses found a stronger association between 12-month mortality and frailty in benign disease (aHR = 4.36, 95% CI 2.17-8.77, p < 0.0001) than in all pleural disease. Malignancy irrespective of frailty status was associated with an increase in all-cause mortality (aHR = 10.40, 95% CI 6.01-18.01, p < 0.0001).
CONCLUSION
CONCLUSIONS
This is the first study evaluating the relationship between frailty and outcomes in pleural disease. Our data demonstrates a strong association between frailty and 12-month mortality in this cohort. A malignant diagnosis is an independent predictor of 12-month mortality, irrespective of frailty status. Frailty was also strongly associated with 12-month mortality in patients with a benign underlying cause for their pleural disease. This has clinical relevance for pleural physicians; evaluating patients' frailty status and its impact on mortality can guide clinicians in assessing suitability for invasive investigation and management.
TRIAL REGISTRATION
BACKGROUND
This study is registered with the Health Research Authority (REC reference 08/H0102/11) and the NIHR Portfolio (Study ID 8960).
Identifiants
pubmed: 38627673
doi: 10.1186/s12890-024-02981-3
pii: 10.1186/s12890-024-02981-3
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
180Informations de copyright
© 2024. The Author(s).
Références
Clegg A, Young J, Iliffe S, Rikkert MO, Rockwood K. Frailty in elderly people. Lancet. 2013;381:752–62.
doi: 10.1016/S0140-6736(12)62167-9
pubmed: 23395245
Fried LP, Tangen CM, Walston J, Newman AB, Hirsch C, Gottdiener J, Seeman T, Tracy R, Kop WJ, Burke G, McBurnie MA. Cardiovascular Health Study Collaborative Research G. Frailty in older adults: evidence for a phenotype. J Gerontol Biol Sci Med Sci. 2001;56:M146–56.
doi: 10.1093/gerona/56.3.M146
Mitnitski AB, Mogilner AJ, Rockwood K. Accumulation of deficits as a proxy measure of aging. ScientificWorldJournal. 2001;1:323–36.
doi: 10.1100/tsw.2001.58
pubmed: 12806071
pmcid: 6084020
Jones DM, Song X, Rockwood K. Operationalizing a Frailty Index from a standardized Comprehensive Geriatric Assessment. J Am Geriatr Soc. 2004;52:1929–33.
doi: 10.1111/j.1532-5415.2004.52521.x
pubmed: 15507074
Lee DH, Buth KJ, Martin B-J, Yip AM, Hirsch GM. Frail patients are at increased risk for mortality and prolonged institutional care after cardiac surgery. Circulation. 2010;121:973–8.
doi: 10.1161/CIRCULATIONAHA.108.841437
pubmed: 20159833
Farhat JS, Velanovich V, Falvo AJ, Horst HM, Swartz A, Patton JH, Rubinfeld IS. Are the frail destined to fail? Frailty index as predictor of surgical morbidity and mortality in the elderly. J Trauma Acute Care Surg. 2012;72:1526–31.
doi: 10.1097/TA.0b013e3182542fab
pubmed: 22695416
Carter B, Keevil VL, Anand A, Osuafor CN, Goudie RJB, Preller J, Lowry M, Clunie S, Shenkin SD, McCarthy K, Hewitt J, Quinn TJ. The prognostic and discriminatory utility of the clinical Frailty Scale and modified Frailty Index compared to age. Geriatrics. 2022;7:87.
doi: 10.3390/geriatrics7050087
pubmed: 36136796
pmcid: 9498791
Kojima G, Iliffe S, Walters K. Frailty index as a predictor of mortality: a systematic review and meta-analysis. Age Ageing. 2018;47:193–200.
doi: 10.1093/ageing/afx162
pubmed: 29040347
Verduri A, Carter B, Rice C, Laraman J, Barton E, Clini E, Maskell NA, Hewitt J. Frailty Prevalence and Association with Clinical outcomes in interstitial lung Disease, Asthma, and Pleural Disease. Geriatr (Basel). 2023; 8.
Subramaniam S, Aalberg JJ, Soriano RP, Divino CM. New 5-Factor modified Frailty Index using American College of Surgeons NSQIP Data. J Am Coll Surg. 2018;226:173–e818.
doi: 10.1016/j.jamcollsurg.2017.11.005
pubmed: 29155268
Weaver DJ, Malik AT, Jain N, Yu E, Kim J, Khan SN. The modified 5-Item Frailty Index: a concise and useful Tool for assessing the impact of Frailty on postoperative morbidity following elective posterior lumbar fusions. World Neurosurg. 2019;124:e626–32.
doi: 10.1016/j.wneu.2018.12.168
pubmed: 30639495
Levine MD, Felix AS, Meade CE, Bixel KL, Chambers LM. The modified 5-item frailty index is a predictor of post-operative complications in vulvar cancer: a National Surgical Quality Improvement Program (NSQIP) analysis. Int J Gynecol Cancer. 2023;33:465–72.
doi: 10.1136/ijgc-2022-004175
pubmed: 36898698
Light RW. Pleural effusions. Med Clin N Am. 2011;95:1055–70.
doi: 10.1016/j.mcna.2011.08.005
pubmed: 22032427
Porcel JM, Esquerda A, Vives M, Bielsa S. Etiology of Pleural effusions: analysis of more than 3,000 consecutive thoracenteses. Archivos De Bronconeumología. (English Edition). 2014;50:161–5.
Komici K, Bencivenga L, Navani N, D’Agnano V, Guerra G, Bianco A, Rengo G, Perrotta F. Frailty in patients with Lung Cancer: a systematic review and Meta-analysis. Chest. 2022;162:485–97.
doi: 10.1016/j.chest.2022.02.027
pubmed: 35217002
Verduri A, Carter B, Laraman J, Rice C, Clini E, Maskell NA, Hewitt J. Frailty and its influence on mortality and morbidity in COPD: a systematic review and Meta-analysis. Intern Emerg Med. 2023;18:2423–34.
doi: 10.1007/s11739-023-03405-6
pubmed: 37668748
pmcid: 10635928
Barton E, Carter B, Verduri A, Hughes J, Hewitt J, Maskell NA. Long term association between frailty and survival in patients with pleural disease: a cohort study protocol. medRxiv 2023020623285492. 2023.
Clive AO, Kahan BC, Hooper CE, Bhatnagar R, Morley AJ, Zahan-Evans N, Bintcliffe OJ, Boshuizen RC, Fysh ETH, Tobin CL, Medford ARL, Harvey JE, van den Heuvel MM, Lee YCG, Maskell NA. Predicting survival in malignant pleural effusion: development and validation of the LENT prognostic score. Thorax. 2014;69:1098–104.
doi: 10.1136/thoraxjnl-2014-205285
pubmed: 25100651
Zamboni MM, da Silva CT, Baretta R, Cunha ET, Cardoso GP. Important prognostic factors for survival in patients with malignant pleural effusion. BMC Pulm Med. 2015;15:29.
doi: 10.1186/s12890-015-0025-z
pubmed: 25887349
pmcid: 4379612
Burrows CM, Mathews WC, Colt HG. Predicting Survival in patients with recurrent symptomatic malignant pleural effusions. Chest. 2000;117:73–8.
doi: 10.1378/chest.117.1.73
pubmed: 10631202
Anevlavis S, Kouliatsis G, Sotiriou I, Koukourakis MI, Archontogeorgis K, Karpathiou G, Giatromanolaki A, Froudarakis ME. Prognostic factors in patients presenting with Pleural Effusion revealing malignancy. Respiration. 2014;87:311–6.
doi: 10.1159/000356764
pubmed: 24457947
National Institute of H, Clinical E. Type 2 diabetes in adults: management. 2022; 1–59.
Chief Operating Officer NHSSD. Chronic Obstructive Pulmonary Disease (COPD): best practice guide. 2017; 1–36.
Public Health E. Hypertension prevalence estimates in England, 2017. 2020; 1–11.
National Centre for H, Clinical E. Chronic Heart Failure in Adults: Diagnosis and Management. London, 2018.
Carter B, Short R, Bouamra O, Parry F, Shipway D, Thompson J, Baxter M, Lecky F, Braude P. A national study of 23 major trauma centres to investigate the effect of frailty on clinical outcomes in older people admitted with serious injury in England (FiTR 1): a multicentre observational study. Lancet Healthy Longev. 2022;3:e540–8.
doi: 10.1016/S2666-7568(22)00122-2
pubmed: 36102763
Hewitt J, Carter B, McCarthy K, Pearce L, Law J, Wilson FV, Tay HS, McCormack C, Stechman MJ, Moug SJ, Myint PK. Frailty predicts mortality in all emergency surgical admissions regardless of age. An observational study. Age Ageing. 2019;48:388–94.
doi: 10.1093/ageing/afy217
pubmed: 30778528
Santoro A, O’Brien ME, Stahel RA, Nackaerts K, Baas P, Karthaus M, Eberhardt W, Paz-Ares L, Sundstrom S, Liu Y, Ripoche V, Blatter J, Visseren-Grul CM, Manegold C. Pemetrexed plus cisplatin or pemetrexed plus carboplatin for chemonaïve patients with malignant pleural mesothelioma: results of the international expanded Access Program. J Thorac Oncology: Official Publication Int Association Study Lung Cancer. 2008;3:756–63.
doi: 10.1097/JTO.0b013e31817c73d6